Pfizer – Global Hemophilia Grant – Equity in Therapeutic Patient Education

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Monday 13th, February 2023

External Deadline: Thursday 16th, February 2023


This grant program seeks to champion patient learning and address both educational equity & quality amongst people living with hemophilia (PLwH) to support them in making evidence-informed decisions in a rapidly evolving treatment landscape.

This competitive grant program is open to Patient Advocacy Groups (PAGs) and non-profit organizations – of all sizes and in all countries – that provide education to PLwH. Submissions from applicants in low-, middle-, and high-income countries will be given equal consideration.

Translations of this RFP in French, Spanish, Mandarin, and Arabic along with further information on Pfizer’s Competitive Grants program can be found at the following link:

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Additional details can be found here.


Date RFP Issued: November 17, 2022

Geographic Scope: Global

Clinical Area: Hemophilia A and B of all severities

Link to full RFP: Global Hemophilia Grant – Equity in Therapeutic Patient Education

Application Due Date: February 16, 2023

Specific Area of Interest: The goal of this RFP is to support projects that address the cultural, socio-economic, geographic location and/or linguistic barriers and any other factors contributing to PLwH’s limited access to novel treatment information and understanding of their clinical needs and role in the decision-making process.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: November 18, 2022